Guanshi Zhang

Sygnamap, Inc.

$331,865

Attributed

$663,729

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $356.5K · FY2021–23

$500K$375K$250K$125K$0

'21

'22

'23

Funding mix

By agency

NIH$663,729 · 2

By mechanism

R43$356,499 · 1

R41$307,230 · 1

Top collaborators

Leila Hejazi2 shared

Most similar at Sygnamap, Inc.

Same institution · by research overlap

Leila Hejazi$485,115

Others in their field

Other Emerging Leaders on “Kidney Diseases”

Chani Eduard · Precision Bioservices, Inc.$19,909,203
Robyn Lorraine Woods · Hennepin Healthcare Research Institute$19,109,927
Barbara Halina Braffett · George Washington University$18,816,779
Ionut Bebu · George Washington University$18,816,779
Noel P Burtt · Broad Institute, Inc.$12,561,765
Vera Hoffman · Reveal Pharma$10,532,099

Research focus

Kidney DiseasesSamplingTechnologyPathway InteractionsInnovationBiological MarkersMolecularStructureChronic DiseaseAwardBiological ProcessAutomationBiomarker DiscoveryBiopsyAnalytical MethodBiochemical PathwayCapillary ElectrophoresisBiochemicalAreaCellsChiral MoleculeChronicCalibrationBlood Specimen

Grant awards (2)

Quantitative Normalization of Spatial Metabolomics for Molecular Signatures of Tissue Heterogeneity$356,499

R43 · FY2023 · GM

On-chip filtration and fractionation components for high-sensitive POC device to measure Chiral Metabolites in Urine$307,230

R41 · FY2021 · GM